- Home
- Publications
- Publication Search
- Publication Details
Title
Fabry Disease: The Current Treatment Landscape
Authors
Keywords
-
Journal
DRUGS
Volume 81, Issue 6, Pages 635-645
Publisher
Springer Science and Business Media LLC
Online
2021-03-15
DOI
10.1007/s40265-021-01486-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)
- (2020) Malte Lenders et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
- (2020) Eleonora Riccio et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Effects of orally delivered alpha-galactosidase A on gastrointestinal symptoms in patients with Fabry disease
- (2020) Malte Lenders et al. GASTROENTEROLOGY
- Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
- (2020) Ulla Feldt-Rasmussen et al. MOLECULAR GENETICS AND METABOLISM
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
- (2020) M. Judith Peterschmitt et al. Clinical Pharmacology in Drug Development
- Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease
- (2019) Julia B. Hennermann et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Migalastat: A Review in Fabry Disease
- (2019) Emma H. McCafferty et al. DRUGS
- Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy
- (2019) Malte Lenders et al. JOURNAL OF MEDICAL GENETICS
- Neutralising anti‐drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity
- (2019) Franciska Stappers et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease
- (2018) Ilya Ruderfer et al. BIOCONJUGATE CHEMISTRY
- Non-specific gastrointestinal features: Could it be Fabry disease?
- (2018) Max J. Hilz et al. DIGESTIVE AND LIVER DISEASE
- Linaclotide for the treatment of chronic constipation
- (2018) Gabrio Bassotti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion
- (2018) Malte Lenders et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions
- (2018) Yunsheng Yang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Fabry disease revisited: Management and treatment recommendations for adult patients
- (2018) Alberto Ortiz et al. MOLECULAR GENETICS AND METABOLISM
- European expert consensus statement on therapeutic goals in Fabry disease
- (2018) Christoph Wanner et al. MOLECULAR GENETICS AND METABOLISM
- Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease
- (2018) Malte Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts
- (2018) Dominique P. Germain et al. MOLECULAR GENETICS AND METABOLISM
- Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
- (2018) Jonas Müntze et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease
- (2018) Malte Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease
- (2017) M. Lenders et al. JOURNAL OF INTERNAL MEDICINE
- Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages
- (2017) Johannes Krämer et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
- (2016) Juan M. Politei et al. CNS Neuroscience & Therapeutics
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
- (2016) Elfrida R. Benjamin et al. GENETICS IN MEDICINE
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- (2016) Derralynn A Hughes et al. JOURNAL OF MEDICAL GENETICS
- Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
- (2016) Dominique P. Germain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
- (2016) Malte Lenders et al. Orphanet Journal of Rare Diseases
- Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society
- (2016) DE Moulin et al. Pain Research & Management
- X-chromosome inactivation in female patients with Fabry disease
- (2015) L. Echevarria et al. CLINICAL GENETICS
- A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease
- (2015) Raphael Schiffmann et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
- (2015) Jin-Song Shen et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
- (2015) Dominique P Germain et al. JOURNAL OF MEDICAL GENETICS
- Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
- (2015) David G Warnock et al. JOURNAL OF MEDICAL GENETICS
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up
- (2015) M. Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
- (2015) M. Lenders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
- (2015) Nanna B Finnerup et al. LANCET NEUROLOGY
- Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease
- (2015) Tali Kizhner et al. MOLECULAR GENETICS AND METABOLISM
- Unknown
- (2015) Karen Ashe et al. MOLECULAR MEDICINE
- Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
- (2015) Christoph Kampmann et al. Orphanet Journal of Rare Diseases
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch
- (2014) F. Weidemann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry
- (2013) Dominique P. Germain et al. GENETICS IN MEDICINE
- Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases
- (2013) Robert E. Boyd et al. JOURNAL OF MEDICINAL CHEMISTRY
- Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease
- (2012) C. Tondel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Sodium Intake, ACE Inhibition, and Progression to ESRD
- (2011) S. Vegter et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS—the Fabry Outcome Survey
- (2011) Derralynn A. Hughes et al. MOLECULAR GENETICS AND METABOLISM
- Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
- (2011) D. G. Warnock et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
- (2010) N. Attal et al. EUROPEAN JOURNAL OF NEUROLOGY
- Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
- (2010) Torquil Watt et al. GENETICS IN MEDICINE
- Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy
- (2009) Frank Weidemann et al. CIRCULATION
- Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onsetGLAmutation c.936+919G>A (IVS4+919G>A)
- (2009) Wuh-Liang Hwu et al. HUMAN MUTATION
- Fabry's disease
- (2008) Yuri A Zarate et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now